Document Detail

Points of action of estrogen antagonists and a calmodulin antagonist within the MCF-7 human breast cancer cell cycle.
MedLine Citation:
PMID:  2706627     Owner:  NLM     Status:  MEDLINE    
Tamoxifen and other structurally related nonsteroidal antiestrogens possess properties in addition to their estrogen antagonist activity including inhibition of both calmodulin and protein kinase C. The present studies were designed to test whether the estrogen-reversible (estrogen receptor mediated) and estrogen-irreversible effects of nonsteroidal antiestrogens on cell cycle progression in vitro were mediated at the same or different points within the cell cycle and if the estrogen-irreversible effects coincided temporally with that of a calmodulin antagonist, R24571. Initial experiments investigated the effects of ICI 164384, a pure estrogen antagonist, on proliferation kinetics in asynchronous cultures of MCF-7 human breast cancer cells. At concentrations greater than 1 nM ICI 164384 significantly reduced growth rate while at greater than or equal to 50 nM, ICI 164384 completely arrested growth after the first 24 h of exposure. Concentrations up to 5 microM failed either to cause more profound effects on growth or induce cytotoxicity. Growth inhibition was associated with a decrease in the proportion of S phase cells and an accumulation of cells in G1 phase, and was completely reversed by the simultaneous addition of equimolar estradiol. In order to identify the points of action within the cell cycle of ICI 164384, and the estrogen-reversible and estrogen-irreversible components of the nonsteroidal estrogen antagonist, hydroxyclomiphene, and the calmodulin antagonist, R24571, experiments were undertaken with MCF-7 cells synchronized by mitotic selection. The mean point of action was assessed by delaying addition of the drugs for increasing time periods following mitotic selection and using DNA flow cytometry to determine the proportion of the population affected by drug administration at a specific time within G1 phase. These studies showed that sensitivity to ICI 164384 was restricted to the early part of G1 phase and that the mean time of action was 4.9 h after the beginning of G1 for this pure estrogen antagonist. The mean times of action of the estrogen-reversible (4.1 h into G1 phase) and estrogen-irreversible (4.1 h) mechanisms of action of hydroxyclomiphene, and R24571 (4.0 h), all appeared to be within a similar time frame in early to mid G1 phase. It is concluded that ICI 164384 inhibits breast cancer cell proliferation by inducing a transition delay in G1 phase and that the point of action of this pure estrogen antagonist in early G1 phase is indistinguishable temporally from that of nonsteroidal antiestrogens and calmodulin antagonists.
E A Musgrove; A E Wakeling; R L Sutherland
Related Documents :
744947 - Neurotrophic control of the cell cycle during amphibian limb regeneration.
1932357 - Automatic classification of cells in cell cycle phases based on ki-67 antigen quantific...
3925997 - Control of dna polymerase alpha, beta and gamma activities in heat- and cold-sensitive ...
17406517 - Cell cycle synchronization of tobacco by-2 cells.
12437297 - Apoptotic cell death is a common response to pathogen attack in oats.
6204557 - Leydig cell hyperplasia due to a testicular embryonal carcinoma producing human chorion...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Cancer research     Volume:  49     ISSN:  0008-5472     ISO Abbreviation:  Cancer Res.     Publication Date:  1989 May 
Date Detail:
Created Date:  1989-06-01     Completed Date:  1989-06-01     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  2984705R     Medline TA:  Cancer Res     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  2398-404     Citation Subset:  IM    
Garvan Institute of Medical Research, St. Vincent's Hospital, Sydney, NSW, Australia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Breast Neoplasms / pathology*
Calmodulin / antagonists & inhibitors*
Cell Cycle / drug effects*
Clomiphene / analogs & derivatives,  pharmacology
DNA / analysis
Estradiol / analogs & derivatives,  pharmacology
Estrogen Antagonists / pharmacology*
Imidazoles / pharmacology
Polyunsaturated Alkamides
Tumor Cells, Cultured
Reg. No./Substance:
0/Calmodulin; 0/Estrogen Antagonists; 0/Imidazoles; 0/Polyunsaturated Alkamides; 50-28-2/Estradiol; 57265-65-3/calmidazolium; 79838-51-0/4-hydroxyclomiphene; 9007-49-2/DNA; 911-45-5/Clomiphene; 98007-99-9/ICI 164384

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Lack of in vitro synergy between etoposide and cis-diamminedichloroplatinum(II).
Next Document:  Down-regulation of a Mr 90,000 heat shock cognate protein during granulocytic differentiation in HL-...